A cerium single-atom catalyst enables targeted catalytic therapy for acute kidney injury via neutrophil hitchhiking.
Saved in:
| Title: | A cerium single-atom catalyst enables targeted catalytic therapy for acute kidney injury via neutrophil hitchhiking. |
|---|---|
| Authors: | Pu, Yinying1 (AUTHOR), Duan, Yangying1 (AUTHOR), Li, Wenhao1 (AUTHOR), Lin, Han2 (AUTHOR), Li, Qiyue1 (AUTHOR), Yin, Binxu1 (AUTHOR), Zhang, Kun1 (AUTHOR) zhang1986kun@126.com, Zhou, Bangguo1,3 (AUTHOR) 913565417@qq.com, Wu, Wencheng1 (AUTHOR) wuwencheng@uestc.edu.cn |
| Source: | Journal of Controlled Release. Apr2025, Vol. 380, p404-416. 13p. |
| Subjects: | Acute kidney failure, Reactive oxygen species, Oxidation-reduction reaction, Oxidative stress, Cerium |
| Abstract: | Reactive oxygen species (ROS) play a major role in driving acute kidney injury (AKI) by causing oxidative stress and triggering inflammatory responses. However, treatment of AKI with traditional nanomedicines is still challenging because of low ROS scavenging efficacy and poor inflammatory chemotactic. Herein, we have constructed a novel cerium single-atom catalyst (A-CeSACs) for AKI catalytic therapy which targets inflammation and mimics several enzymatic redox activities. After injection of A-CeSACs into AKI mice via tail vein, targeting damaged kidney sites is realized by hitchhiking neutrophils that naturally target sites of inflammation via chemotaxis. After entering the AKI inflammatory environment, A-CeSACs rapidly scavenge multiple ROS via the Ce3+/Ce4+ redox reaction, thus reducing the release of inflammatory factors. The designed A-CeSACs displayed remarkably catalytic therapy efficacy in glycerol-induced AKI mice models. Overall, the present study describes a novel therapeutic strategy for targeted AKI catalytic therapy that is also potentially applicable to other inflammation-related diseases. [Display omitted] • Novel-synthesied cerium single-atom catalysts with multi-enzyme activities for effectively ROS scavenging. • A novel strategy for AKI targeted delivery of antioxidants by neutrophils hitchhiking. • Highly efficient AKI-targeted antioxidant therapy. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
Be the first to leave a comment!
